Sidley represented IDG Capital as the lead investor in HiFiBiO Therapeutics’ US$67 million Series C Financing. HiFiBiO Therapeutics is a global biotech company focused on mobilizing the human immune system to combat disease. IDG Capital led the round with the support of new investors, including Kite Pharma, Delian Capital and Hanne Capital. Existing investors who supported this round included Sequoia Capital China, VI Ventures, Legend Star Capital and LYFE Capital.
The Sidley team was led by partner Ruchun Ji (Shanghai) with assistance from partners Lei Li (Beijing and Shanghai), Thomas Duley (San Francisco) and Samuel Tiu (Los Angeles), counsel Stephen Arbreu, as well as associates Calamus Huang and Henry Cao.
